J 2018

Treatment of coronary in-stent restenosis: a systematic review

PLEVA, Leos, Pavel KUKLA and Ota HLINOMAZ

Basic information

Original name

Treatment of coronary in-stent restenosis: a systematic review

Authors

PLEVA, Leos (203 Czech Republic, guarantor), Pavel KUKLA (203 Czech Republic) and Ota HLINOMAZ (203 Czech Republic, belonging to the institution)

Edition

Journal of Geriatric Cardiology, Beijing, Science Press, 2018, 1671-5411

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30201 Cardiac and Cardiovascular systems

Country of publisher

China

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 1.763

RIV identification code

RIV/00216224:14110/18:00104044

Organization unit

Faculty of Medicine

DOI

UT WoS

000429624200007

Keywords in English

Drug-eluting balloon; Drug-eluting stent; In-stent restenosis

Tags

Tags

International impact, Reviewed
Změněno: 11/2/2019 15:38, Soňa Böhmová

Abstract

V originále

Coronary stent implantation has significantly improved percutaneous coronary intervention and enabled the management of early complications of plain balloon angioplasty. However, a new complication has accompanied these improvements: in-stent restenosis (ISR) arising from neointimal hyperplasia. ISR after coronary angioplasty is currently one of the main limitations of this method, leading to the recurrence of exertional angina pectoris or acute coronary syndromes. The clinical incidence of ISR after bare-metal stent (BMS) implantation is approximately 20%-35%. The use of drug-eluting stents (DES) has led to a further decrease in the occurrence of ISR to 5%-10%. Evidence resulting from controlled clinical studies suggests that DES and drug-eluting balloon catheters (DEB) provide the best clinical and angiographic results in the treatment of ISR. We undertook a systematic review of the pathophysiology, diagnostics and treatment options for BMS- and DES-ISR. We discuss recent randomised studies, comparing different DES or DEB used for BMS or DES-ISR treatment, as well as the use of new biovascular scafolds and the topic of scafold restenosis.